Patients with severe asthma can receive biological treatment comprising anti‐IgE, anti‐IL‐5/anti‐IL5R, anti‐IL‐4R and anti‐TSLP; the allocation criteria is based on an algorithm comprising phenotyping, endotyping including several biomarkers and the presence of comorbidities as presented by GINA 2024.1, 3. Here, IGHE is linked to asthma.